- Home
- SGMT
as 07-26-2024 4:00pm EST
Stocks
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 98.6M | IPO Year: | 2023 |
| Target Price: | $35.80 | AVG Volume (30 days): | 563.6K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -38.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.13 - $20.71 | Next Earning Date: | 08-19-2024 |
| Revenue: | $2,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Sagimet Biosciences Inc. Series A (SGMT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Happel David | SGMT | President & CEO | Mar 26 '24 | Buy | $5.27 | 12,100 | $63,730.70 | 639,200 | SEC Form 4 |
| Happel David | SGMT | President & CEO | Nov 16 '23 | Buy | $2.35 | 590 | $1,386.50 | 590 | SEC Form 4 |
Latest Sagimet Biosciences Inc. Series A News
SGMT Breaking Stock News: Dive into SGMT Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
2 months ago
Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*
PR Newswire
2 months ago
NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
Business Wire
2 months ago
Form 8.3 - International Distribution Services plc
Business Wire
2 months ago
Form 8.3 - Darktrace plc
Reuters
2 months ago
US Supreme Court rejects Kroger challenge to Grubhub trademark win
Investor's Business Daily
2 months ago
Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect
Business Wire
2 months ago
GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina
Compare SGMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGMT Sagimet Biosciences Inc. Series A - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.